Vama Health World LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vama Health World LLP Pharmaceutical Export Portfolio Dataset — 3 Products, $246.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vama Health World LLP — Pharmaceutical Exporter Profile (2026) | 3 Products, $246.6K Trade | TransData Nexus

Vama Health World LLP

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $246.6K Total Trade · DGFT Verified

Vama Health World LLP is an Indian pharmaceutical exporter with a total trade value of $246.6K across 3 products in 2 therapeutic categories. Based on 36 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Etanercept ($108.5K), Olaparib ($107.6K), Nilotinib ($30.5K).

Vama Health World LLP — Export Portfolio & Destination Treemap

Vama Health World LLP pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vama Health World LLP? — Company Overview & Market Position

Vama Health World LLP is a pharmaceutical company based in Mumbai, Maharashtra, India. Established on July 27, 2016, the company operates under the Limited Liability Partnership (LLP) structure, with the Corporate Identification Number (CIN) AAH-0237. The registered office is located at Unit No. 011, Peninsula Centre, Dr. S. S. Rao Road, Parel East, Mumbai, Maharashtra, 400012. The company is led by Designated Partners Girish Ramesh Rathod, Shama Rathod Girish, and Mangesh Madanlal Dhalawat. Vama Health World LLP specializes in the distribution and retail of specialty pharmaceutical products, focusing on areas such as oncology, hematology, dermatology, and critical care. The company has a dedicated team with over 20 years of experience in the pharmaceutical distribution sector.

What Does Vama Health World LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Etanercept$108.5K 2Olaparib$107.6K

Product Portfolio — Top 3 by Export Value

Vama Health World LLP exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Etanercept	Biologics & Immunotherapy	$108.5K	10	0.2%	5
2	Olaparib	Advanced Oncology	$107.6K	20	11.7%	3
3	Nilotinib	Advanced Oncology	$30.5K	6	2.4%	2

Vama Health World LLP exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $246.6K. The top category is Advanced Oncology (56.0% of portfolio), followed by Biologics & Immunotherapy (44.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vama Health World LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vama Health World LLP operates manufacturing facilities in Maharashtra and Gujarat, India. These sites are equipped with modern technology and adhere to global standards, ensuring the production of high-quality pharmaceutical products. The facilities are certified by various international regulatory bodies, including the US FDA, EDQM, and WHO-PQ, reflecting the company's commitment to maintaining stringent quality control measures.

3Key Leadership

The leadership team at Vama Health World LLP comprises Designated Partners Girish Ramesh Rathod, Shama Rathod Girish, and Mangesh Madanlal Dhalawat. Girish Ramesh Rathod has been associated with the company since January 5, 2017, bringing extensive experience in the pharmaceutical industry. Shama Rathod Girish and Mangesh Madanlal Dhalawat have been with the company since its inception on July 27, 2016, contributing to its growth and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vama Health World LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vama Health World LLP has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from the US FDA, EDQM, and WHO-PQ, indicating compliance with international quality standards. These certifications facilitate market access and regulatory approvals in these regions. The company's product portfolio, which includes formulations such as Etanercept, Olaparib, and Nilotinib, aligns with the therapeutic needs of these markets, particularly in oncology and immunotherapy.

2Emerging Markets

Vama Health World LLP has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to global standards and possession of certifications like WHO prequalification enable it to meet the regulatory requirements of these regions. This strategic expansion allows the company to address the growing demand for quality pharmaceutical products in these markets, particularly in therapeutic areas such as oncology and critical care.

3Geographic Strategy

Vama Health World LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vama Health World LLP's manufacturing facilities are registered with the US Food and Drug Administration (FDA), indicating compliance with US regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for its product portfolio, including Etanercept, Olaparib, and Nilotinib, facilitating market access in the United States. The facilities have undergone FDA inspections, receiving favorable outcomes, which underscores the company's commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

The manufacturing facilities of Vama Health World LLP are certified by the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates. These certifications attest to the company's adherence to international quality standards, ensuring the safety and efficacy of its pharmaceutical products. The EU GMP certification, in particular, facilitates market access within the European Union, enabling the company to distribute its products across member states.

3CDSCO & Indian Regulatory

Vama Health World LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vama Health World LLP operates in a competitive landscape, with several pharmaceutical companies offering similar products in the oncology and immunotherapy sectors. While specific market share data for competitors is not available, the company's focus on high-quality manufacturing, adherence to international standards, and strategic geographic diversification provide it with a competitive edge. The company's product portfolio, including Etanercept, Olaparib, and Nilotinib, positions it to meet the therapeutic needs of various markets, enhancing its competitiveness.

2Key Differentiators

Vama Health World LLP's key differentiators include its extensive experience in pharmaceutical distribution, with over 20 years in the industry, and its commitment to quality, as evidenced by certifications from regulatory bodies such as the US FDA, EDQM, and WHO-PQ. The company's strategic focus on specialty pharmaceutical products, particularly in oncology and immunotherapy, allows it to address specific therapeutic needs, setting it apart from competitors. Additionally, its diversified geographic presence mitigates market risks and leverages growth opportunities in emerging markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Vama Health World LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vama Health World LLP has demonstrated a consistent track record in pharmaceutical distribution, with over 20 years of experience in the industry. The company's export volume and consistency are supported by its adherence to international quality standards and certifications from regulatory bodies such as the US FDA, EDQM, and WHO-PQ. Reliability indicators include the absence of adverse regulatory actions and the company's strategic focus on specialty pharmaceutical products, which align with global therapeutic needs.

2Certifications to Verify

Importers should verify the following certifications to ensure the quality and compliance of Vama Health World LLP's products:

FDA Registration: Confirm the company's manufacturing facilities are registered with the US FDA. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure the company holds certification from the World Health Organization's Good Manufacturing Practice program. This can be verified by reviewing the company's certifications or contacting WHO directly.

Frequently Asked Questions — Vama Health World LLP

How many pharmaceutical products does Vama Health World LLP export from India?

Vama Health World LLP exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Etanercept ($108.5K), Olaparib ($107.6K), Nilotinib ($30.5K). Total export value is $246.6K.

What is Vama Health World LLP's total pharmaceutical export value?

Vama Health World LLP's total pharmaceutical export value is $246.6K, based on 36 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vama Health World LLP cover?

Vama Health World LLP exports across 2 therapeutic categories. The largest are Advanced Oncology (56.0%, 2 products), Biologics & Immunotherapy (44.0%, 1 products).

Get Full Vama Health World LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.